|
시장보고서
상품코드
2050693
유도만능줄기세포 시장 : 세포 유래별, 용도별, 최종사용자별, 지역별Induced Pluripotent Stem Cells Market, By Cell Source, By Application, By End User, By Geography |
||||||
유도만능줄기세포(iPS 세포) 시장은 2026년에 17억 8,300만 달러로 추정되고 있으며, 2033년까지 38억 2,010만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 11.5%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 17억 8,300만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 11.50% | 2033년 시장 규모 예측 : | 38억 2,010만 달러 |
유도만능줄기세포(iPS 세포)는 성체세포에서 직접 만들 수 있는 만능줄기세포의 일종입니다. 유도만능줄기세포의 발견은 배아줄기세포를 대체할 수 있는 윤리적으로 우수한 대안을 제공함으로써 재생의료 분야에 혁명을 일으켰습니다. 유도만능줄기세포(iPS 세포)는 배아줄기세포와 유사한 다능성 상태로 유전적으로 재프로그래밍된 성체세포입니다. iPS 세포는 질병 기전 규명 및 신약 개발, 독성 스크리닝을 목적으로 한 재생의료 연구에 활용되고 있습니다. iPS 세포의 재생 능력은 세포를 이용한 치료제 개발의 가능성을 넓히고 있습니다. 이 세포들은 원래 분화된 성체 세포에서 분화능과 다능성 마커의 발현에서 배아줄기세포와 유사한 상태로 역행할 수 있도록 하는 중요한 전사인자의 도입 또는 과발현을 통해 원래의 분화된 성체 세포에서 재프로그래밍됩니다. 이 기술은 신약개발, 독성 스크리닝, 재생의료를 위한 환자 및 질병에 특화된 줄기세포 모델 개발에 큰 기대를 모으고 있습니다.
시장 역학
세계의 iPS 세포 시장은 만성질환의 유병률 증가, 장기 이식의 보급 확대, 그리고 새로운 줄기세포 기반 치료제 개발을 위한 바이오 제약사들의 연구개발(R&D) 투자 증가에 힘입어 성장하고 있습니다. 그러나 iPS 세포의 연구 및 임상 적용에 따른 높은 비용, 세포 재프로그래밍 및 줄기세포 분화에 대한 기술적 문제 등이 시장의 성장을 저해하고 있습니다. 한편, 표준 배양법 확립, 이종 유래 성분을 포함하지 않는 리프로그래밍 방법의 개발, 대규모 줄기세포 생산의 진전 등 줄기세포 기술의 지속적인 발전은 시장 관계자들에게 유망한 성장 기회를 제공할 것으로 예상됩니다.
본 조사의 주요 특징
- 이 조사에서는 각 부문의 잠재적 매출 성장 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개변수(회사 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략)를 기반으로 세계의 유도만능줄기세포(iPS 세포) 시장의 주요 기업 개요을 작성했습니다.
- 본 조사에서 다루어지고 있는 주요 기업에는 Takara Bio Inc., Thermo Fisher Scientific, Fujifilm Holdings Corporation, Astellas Pharma, Fate Therapeutics, Ncardia, ViaCyte, Cellular Dynamics International, Lonza, Blueprint Medicines 및 기타 유력 기업이 포함됩니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 세계의 iPS 세포 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 글로벌 iPS 세포 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 유도만능줄기세포 시장 : 세포원별, 2021-2033년
제5장 세계의 유도만능줄기세포 시장 : 용도별, 2021-2033년
제6장 세계의 유도만능줄기세포 시장 : 최종사용자별, 2021-2033년
제7장 세계의 유도만능줄기세포 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSA 26.06.10Induced Pluripotent Stem Cells Market is estimated to be valued at USD 1,783.0 Mn in 2026 and is expected to reach USD 3,820.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 11.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,783 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.50% | 2033 Value Projection: | USD 3,820.1 Mn |
Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The discovery of induced pluripotent stem cells revolutionized the field of regenerative medicine as it provided an ethically superior alternative to embryonic stem cells. Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to an embryonic stem cell-like pluripotent state. iPSCs are used in regenerative medicine research to study mechanisms of disease and for drug discovery and toxicity screening. Regenerative properties of iPSCs provide opportunities for developing cell-based therapies. These cells are reprogrammed from their original differentiated adult cells through the introduction or overexpression of key transcription factors that enable them to regress to a state that resembles embryonic stem cells in terms of differentiation potential and expression of pluripotency markers. This technology holds tremendous promise for developing patient and disease specific stem cell models for drug discovery, toxicity screening, and regenerative therapies.
Market Dynamics
Global induced pluripotent stem cells market is driven by rising prevalence of chronic diseases, increasing adoption of organ transplantation and growing research and development (R&D) investments by biopharmaceutical companies for developing novel stem cell-based therapies. However, high costs that are associated with iPSC research and clinical applications, technical challenges in cell reprogramming and stem cell differentiation are restraining wider market growth. Meanwhile, ongoing advancements in stem cell technologies including establishment of standard culture practices, development of xeno-free reprogramming methods and progress in large-scale stem cell production are expected to offer lucrative growth opportunities for market players.
Key features of the study
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global induced pluripotent stem cells market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- The key companies covered as a part of this study include Takara Bio Inc., Thermo Fisher Scientific, Fujifilm Holdings Corporation, Astellas Pharma, Fate Therapeutics, Ncardia, ViaCyte, Cellular Dynamics International, Lonza, Blueprint Medicines, and Other Prominent Players.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- Global induced pluripotent stem cells market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global induced pluripotent stem cells market.
Market Segmentation
- By Cell Source (Revenue, USD Mn, 2021 - 2033)
- Skin derived iPSCs
- Blood derived iPSCs
- Urine Derived iPSCs
- Hepatocytes derived iPSCs
- Lung fibroblast derived iPSCs
- Others (Endothelial cells, Glial Cells, Adipose stem cells etc.)
- By Application (Revenue, USD Mn, 2021 - 2033)
- Culture & Maintenance
- Differentiation
- Genetic Manipulation & Engineering
- Characterization & Validation
- Banking & Storage
- Others (Reprogramming kits, Analysis software etc.)
- By End User (Revenue, USD Mn, 2021 - 2033)
- Hospitals
- Diagnostics Centers
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Others (Academic & Research Institutes etc.)
- By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top Companies in the Global Induced Pluripotent Stem Cells Market
- Takara Bio Inc.
- Thermo Fisher Scientific
- Fujifilm Holdings Corporation
- Astellas Pharma
- Fate Therapeutics
- Ncardia
- ViaCyte
- Cellular Dynamics International
- Lonza
- Blueprint Medicines
- Other Prominent Players
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Induced Pluripotent Stem Cells Market Snippet, By Cell Source
- Global Induced Pluripotent Stem Cells Market Snippet, By Application
- Global Induced Pluripotent Stem Cells Market Snippet, By End User
- Global Induced Pluripotent Stem Cells Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Key Highlights
- Regulatory Scenario
- Recent Trends
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Induced Pluripotent Stem Cells Market, By Cell Source, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Skin derived iPSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Blood derived iPSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Urine Derived iPSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Hepatocytes derived iPSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Lung fibroblast derived iPSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Others (Endothelial cells, Glial Cells, Adipose stem cells etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
5. Global Induced Pluripotent Stem Cells Market, By Application, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Culture & Maintenance
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Differentiation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Genetic Manipulation & Engineering
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Characterization & Validation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Banking & Storage
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Others (Reprogramming kits, Analysis software etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
6. Global Induced Pluripotent Stem Cells Market, By End User, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Diagnostics Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Pharmaceutical & Biotechnology Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Contract Research Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Others (Academic & Research Institutes etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
7. Global Induced Pluripotent Stem Cells Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cell Source, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033,(USD Mn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Company Profile
- Takara Bio Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Fujifilm Holdings Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Fate Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Ncardia
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- ViaCyte
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cellular Dynamics International
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lonza
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Blueprint Medicines
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Other Prominent Players
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takara Bio Inc.
- Analyst Views
9. Section
- References
- Research Methodology
- About us
